RxDoctor Payments Data

Emma-Catherine Ali

Optometrist · Roanoke, VANPI 1629205232

Payments from drug & device makers

$3,370in general payments, 2019–2025

Across 85 payments — averaging $39.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$2K
  • Alcon$662
  • Johnson & Johnson Vision Care, Inc.$255
  • Bausch & Lomb Americas Inc.$255
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$178
  • Tarsus Pharmaceuticals, Inc.$145
  • plus $322 from 10 others

What the payments were for

  • Travel & lodging$97429%
  • Food & beverage$2,37671%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,370 in reported general payments places this provider in the 80th percentile of 1,230 optometrist providers in Virginia.

See all optometrist providers in Virginia

Medicare billing

Part B allowed, 2024
$251,300
Medicare patients
1,205
Services billed
2,642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost54$32,590
MieboPerfluorohexyloctane/Pf18$13,594
RestasisCyclosporine11$13,276
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$3,566
Travoprost12$2,897
Ketorolac Tromethamine197$2,425
Latanoprost275$2,378
Prednisolone Acetate60$2,366
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha196$2,179
Doxycycline Hyclate128$1,495
Timolol Maleate133$1,343
Brimonidine Tartrate21$1,098
Tobramycin-DexamethasoneTobramycin/Dexamethasone21$1,043
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat67$1,021
Azelastine Hcl38$773

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$13$45,86665 claims
Bausch & Lomb Americas Inc.Miebo$255$13,59418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,230 optometrist providers in Virginia.

Other optometrist in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →